COPENHAGEN, Denmark, June 18, 2026
Allarity Therapeutics, Inc. announced the presentation of a Trial-in-Progress poster for its ongoing Phase 2 clinical trial evaluating stenoparib (2X-121) in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer at the ESMO Gynaecological Cancers Congress 2026. The poster, presented by renowned gynecologic oncologist Kathleen N. Moore, M.D., outlines the study’s scientific rationale and trial design while highlighting stenoparib’s dual mechanism of action targeting both PARP and WNT signaling pathways. As a Trial-in-Progress presentation, the poster does not include new efficacy or safety data, but emphasizes the potential of the investigational therapy to address a significant unmet need in difficult-to-treat ovarian cancer.
Phase 2 Trial Builds on Encouraging Clinical Experience
The ongoing Phase 2 study (NCT03878849) was designed following encouraging findings from Allarity’s earlier Phase 2 trial, where stenoparib demonstrated durable clinical benefit in heavily pretreated ovarian cancer patients. The amended protocol specifically enrolls patients with platinum-resistant or platinum-ineligible ovarian cancer, aiming to accelerate the drug’s clinical development toward potential FDA approval. Stenoparib is an oral dual PARP1/2 and tankyrase 1/2 inhibitor, a differentiated approach intended to simultaneously inhibit DNA repair while blocking WNT/β-catenin signaling, a pathway strongly associated with tumor progression and treatment resistance. The company believes this dual-targeted strategy could provide a more effective therapeutic option for patients who have limited treatment alternatives.
DRP® Precision Medicine Strategy Supports Patient Selection
A key component of the development program is Allarity’s proprietary Drug Response Predictor (DRP®) companion diagnostic platform, which analyzes messenger RNA (mRNA) gene expression profiles to identify patients most likely to benefit from stenoparib treatment. By selecting patients with favorable molecular signatures before therapy, the company aims to improve response rates while advancing a personalized medicine approach in ovarian cancer. According to Chief Executive Officer Thomas Jensen, presenting the study at ESMO Gynaecological Cancers Congress 2026 provides an important opportunity to introduce the scientific rationale behind the trial and the DRP®-guided precision oncology strategy to leading gynecologic oncology experts across Europe and the United States. The company also noted that the poster will be made available on its website following the presentation.
Advertisement
Broader Oncology Development Continues Beyond Ovarian Cancer
Beyond ovarian cancer, Allarity Therapeutics is expanding stenoparib’s clinical development into additional oncology indications. A separate Phase 2 clinical trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) is currently enrolling patients across multiple U.S. Veterans Affairs clinical sites. Originally developed by Eisai Co., Ltd., stenoparib was later exclusively licensed by Allarity for global development and commercialization. By combining dual pathway inhibition with biomarker-driven patient selection, the company aims to improve treatment outcomes in cancers with high unmet medical needs while advancing a precision oncology strategy that could support future regulatory submissions.
Source: Allarity Therapeutics press release
